KR-POK interacts with p53 and represses its ability to activate transcription of p21WAF1/CDKN1A

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1137-1148

  Jeon, Bu Nam ^a   Kim, Min Kyeong ^a   Choi, Won Il ^a   Koh, Dong In ^a   Hong, Sung Yi ^b   Kim, Kyung Sup ^a   Kim, Minjung ^a   Yun, Chae Ok ^a   Yoon, Juyong ^b   Choi, Kang Yell ^b   Lee, Kyung Ryul ^c   Nephew, Kenneth P ^d   Hur, Man Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c BioCore Company   (South Korea)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H3; HISTONE H4; MESSENGER RNA; NUCLEAR RECEPTOR COREPRESSOR; ONCOPROTEIN; PROTEIN BCOR; PROTEIN KR POK; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 1A GENE; DEACETYLATION; DNA DAMAGE; EMBRYO; FEMALE; GENE; GENE FUNCTION; GENE INTERACTION; GENE REPRESSION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KR POK GENE; MOUSE; NONHUMAN; OLIGOMERIZATION; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FIBROBLASTS; GENE KNOCKOUT TECHNIQUES; GENES, P53; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NIH 3T3 CELLS; PROMOTER REGIONS, GENETIC; PROTEINS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; ZINC FINGERS;

EID: 84863275898     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2433     Document Type: Article

References (48)

1. Aravind L, Koonin EV. Fold prediction and evolutionary analysis of the POZ domain: structural and evolutionary relationship with the potassium channel tetramerization domain. J Mol Biol 1999;285: 1353-61. (Pubitemid 29060438)
2. Koonin EV, Senkevich TG, Chernos VI. A family ofDNAvirus genes that consists of fused portions of unrelated cellular genes. Trends Biochem Sci 1992;17:213-4.
3. Costoya JA. Functional analysis of the role of POK transcriptional repressors. Brief Funct Genomic Proteomic 2007;6:8-18. (Pubitemid 351721044)
4. Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, Torchia J, et al. A complex containing NCoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997;387: 43-8. (Pubitemid 27202643)
5. Kadosh D, Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997;89:365-71.
6. Kelly KF, Daniel JM. POZ for effect-POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006;16:578-87. (Pubitemid 44636217)
7. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-4. (Pubitemid 28099682)
8. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89: 373-80. (Pubitemid 27220882)
9. Barna M, Hawe N, Niswander L, Pandolfi PP. Plzf regulates limb and axial skeletal patterning. Nat Genet 2000;25:166-72. (Pubitemid 30394986)
10. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004;36:653-9. (Pubitemid 38715996)
11. He X, He X, Dave VP, Zhang Y, Hua X, Nicolas E, et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 2005;433:826-33. (Pubitemid 40314886)
12. Sun G, Liu X, Mercado P, Jenkinson SR, Kypriotou M, Feigenbaum L, et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat Immunol 2005;6: 373-81. (Pubitemid 41716777)
13. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993;12:1161-7. (Pubitemid 23095865)
14. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 2004;6:387-98. (Pubitemid 39361439)
15. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997;57:1678-81. (Pubitemid 27199658)
16. Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C, et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 1993;5:66-70. (Pubitemid 23261521)
17. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005;433:278-85.
18. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432: 635-9. (Pubitemid 39626271)
19. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005;6:1054-60. (Pubitemid 41486191)
20. Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, Xavier RJ, et al. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood 2010;115:5376-84.
21. Jeon BN, Choi WI, Yu MY, Yoon AR, Kim MH, Yun CO, et al. ZBTB2, a novel master regulator of the p53 pathway. J Biol Chem 2009;284: 17935-46.
22. Koh DI, Choi WI, Jeon BN, Lee CE, Yun CO, Hur MW,et al. A novelPOK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. J Biol Chem 2009;284:19856-66.
23. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006;103:18739-44. (Pubitemid 44913480)
24. Tatard VM, Xiang C, Biegel JA, Dahmane N. ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth. Cancer Res 2010;70:1236-46.
25. Weber A, Marquardt J, Elzi D, Forster N, Starke S, Glaum A, et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J 2008;27:1563-74. (Pubitemid 351794031)
26. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116: 221-34. (Pubitemid 38167314)
27. Besson A, Dowdy SF, Roberts JM.CDKinhibitors: cell cycle regulators and beyond. Dev Cell Rev 2008;14:159-69. (Pubitemid 351189186)
28. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25. (Pubitemid 23346378)
29. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53- mediated G1 arrest in human cancer cells. Cancer Res 1995;55: 5187-90.
30. Gartel AL. p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 2009;35:161-4.
31. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997;17:4877-82. (Pubitemid 27318163)
32. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell cycle arrest versus cell death in cancer therapy. Nat Med 1997;3: 1034-6. (Pubitemid 27391962)
33. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501. (Pubitemid 28538613)
34. Lane D. How cells choose to die. Nature 2001;414:25-7. (Pubitemid 33041606)
35. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
36. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
37. Lane D. p53, guardian of the genome. Nature 1992;358:15-6.
38. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 2001;3: 277-86.
39. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death and Differentiation 2003;10: 404-8. (Pubitemid 36636906)
40. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol 2000;33:1-6. (Pubitemid 30064481)
41. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981-93. (Pubitemid 30253006)
42. Reuter S, Bartelmann M, Vogt M, Geisen C, Napierski I, Kahn T, et al. APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO J 1998;17:215-22. (Pubitemid 28041062)
43. Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res 2009;37:78-95.
44. Banerjee T, Nath S, Roychoudhury S. DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling. Nucleic Acids Res 2009;37:2688-98.
45. Van Bodegom D, Saifudeen Z, Dipp S, Puri S, Magenheimer BS, Calvet JP, et al. The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J Biol Chem 2006; 281:31234-44. (Pubitemid 46041388)
46. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999;13: 2490-501. (Pubitemid 29489641)
47. Zeng Y, Kotake Y, Pei XH, Smith MD, Xiong Y. p53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb. Cancer Res 2011;71:2781-92.
48. Cui J, Yang Y, Zhang C, Hu P, Kan W, Bai X, et al. FBI-1 functions as a novel AR co-repressor in prostate cancer cells. Cell Mol Life Sci 2011;68:1091-103.